Supplementary Figure 4 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer by Matthew T. Campbell (15096440)

“…<p>Flow cytometry of immune cells from serially collected blood samples with evidence of significant decrease in circulating NK cells in: A) Metastatic renal cell carcinoma cohort. …”

VCC monomer and pre-formed oligomer induce pro-inflammatory responses in the BMDCs. by Shraddha Gandhi (21001590)

“…<p>(A) Dose-dependent increase in cytotoxicity in BMDCs upon treatment with VCC monomer (left panel), and pre-formed VCC oligomer generated in the liposomes (right panel). …”

Image 1_Myristic acid beneficially modulates intervertebral disc degeneration by preventing endplate osteochondral remodeling and vertebral osteoporosis in naturally aged mice.pdf by Yan Gong (103494)

“…Additionally, MA notably inhibited osteoclast activity, as evidenced by a decrease in the number of osteoclasts and a significant suppression of F-actin formation. …”

Canopy effects from biomass utilization on the Priest River Experimental Forest by Ina S. Miller (19658593)

“…Our BRDI research goals, targeted the soil and water component of the area where the biomass was removed once reduction had taken place These goals examined whether biomass reduction/removal indicated a significant increase in soil erosion, decrease in infiltration or otherwise adversely impact water resources, compared to control sites. …”

Data Sheet 2_Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors vs glucagon-like peptide 1 receptor agonists in elderly patients with type 2 diabetes... by Yao Wang (102387)

“…</p>Conclusion<p>In conclusion, although SGLT2i increase the risk of EKA and GUI and GLP-1RA decrease the risk of AKI, SGLT2i are at comparable risk of MACE, HHF, MI, stroke, hypoglycemia, and fracture to GLP-1RA.…”

Data Sheet 1_Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors vs glucagon-like peptide 1 receptor agonists in elderly patients with type 2 diabetes... by Yao Wang (102387)

“…</p>Conclusion<p>In conclusion, although SGLT2i increase the risk of EKA and GUI and GLP-1RA decrease the risk of AKI, SGLT2i are at comparable risk of MACE, HHF, MI, stroke, hypoglycemia, and fracture to GLP-1RA.…”

Data Sheet 1_DYRK1A roles in human neural progenitors.docx by Jeremie Courraud (20871932)

“…In addition, DYRK1A-KD led to a reduction in p21 protein levels, despite an increase in the expression of a minor transcript variant for this gene, and a decrease in ERK pathway activation.…”

The analyzed data of the 532 cases of this study. by Qiaolin Yu (9921122)

“…Compared with well-nourished group, the abnormal group showed a decrease in the BBS scores [(52.55 ± 7.10) vs (43.20 ± 16.29), <i><i>p</i></i> < 0.05], and an increase in the TUG [9.00 (7.00, 10.00) vs 9.00 (7.40, 12.00), <i><i>p</i></i> < 0.05] and the FTSST [12.00 (9.00, 14.75) vs 15.00 (10.00, 20.10), <i><i>p</i></i> < 0.05]. …”

Table 1_Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors vs glucagon-like peptide 1 receptor agonists in elderly patients with type 2 diabetes mell... by Yao Wang (102387)

“…</p>Conclusion<p>In conclusion, although SGLT2i increase the risk of EKA and GUI and GLP-1RA decrease the risk of AKI, SGLT2i are at comparable risk of MACE, HHF, MI, stroke, hypoglycemia, and fracture to GLP-1RA.…”

AgTL2 embryos have altered lipids, metabolites, and transcriptional profiles during development. by Maurice A. Itoe (9930475)

“…(C) Heatmap of metabolites analyzed by LC-MS showing levels of the 60 most highly dysregulated metabolites in AgTL2 embryos compared to controls throughout development (values of <i>t</i> test statistic, range: blue to red = significant decrease to increase) (3 biological replicates represented by triplicate columns at each time point). …”

Table 3_Ageing, clinical complexity, and exercise therapy: a multidimensional approach.docx by Salvatore Corrao (441339)

“…Ageing represents the primary risk factor for chronic degenerative diseases, especially involving cardiovascular, metabolic, respiratory, and osteoarticular systems, determining the decrease in activities and quality of daily life. Regular physical activity can significantly reduce the risk of chronic degenerative diseases, moderate or severe functional limitations, and premature death in older adults. …”

Table 1_Ageing, clinical complexity, and exercise therapy: a multidimensional approach.docx by Salvatore Corrao (441339)

“…Ageing represents the primary risk factor for chronic degenerative diseases, especially involving cardiovascular, metabolic, respiratory, and osteoarticular systems, determining the decrease in activities and quality of daily life. Regular physical activity can significantly reduce the risk of chronic degenerative diseases, moderate or severe functional limitations, and premature death in older adults. …”

Table 2_Ageing, clinical complexity, and exercise therapy: a multidimensional approach.docx by Salvatore Corrao (441339)

“…Ageing represents the primary risk factor for chronic degenerative diseases, especially involving cardiovascular, metabolic, respiratory, and osteoarticular systems, determining the decrease in activities and quality of daily life. Regular physical activity can significantly reduce the risk of chronic degenerative diseases, moderate or severe functional limitations, and premature death in older adults. …”

Image 5_Unexpected estradiol decline during ovarian stimulation monitoring affects cumulative live birth.png by Haixiao Chen (12565087)

“…In both unmatched and matched cohorts, the CLBRs were significantly decreased (unmatched cohort: 66.3% versus 55%, P<0.001, adjusted OR 0.83, 95% CI: 0.76,0.91; matched cohort: 59% versus 55%, P = 0.003, adjusted OR 0.84, 95%CI: 0.75,0.94). …”

Image 9_Unexpected estradiol decline during ovarian stimulation monitoring affects cumulative live birth.tiff by Haixiao Chen (12565087)

“…In both unmatched and matched cohorts, the CLBRs were significantly decreased (unmatched cohort: 66.3% versus 55%, P<0.001, adjusted OR 0.83, 95% CI: 0.76,0.91; matched cohort: 59% versus 55%, P = 0.003, adjusted OR 0.84, 95%CI: 0.75,0.94). …”

Image 1_Unexpected estradiol decline during ovarian stimulation monitoring affects cumulative live birth.jpeg by Haixiao Chen (12565087)

“…In both unmatched and matched cohorts, the CLBRs were significantly decreased (unmatched cohort: 66.3% versus 55%, P<0.001, adjusted OR 0.83, 95% CI: 0.76,0.91; matched cohort: 59% versus 55%, P = 0.003, adjusted OR 0.84, 95%CI: 0.75,0.94). …”

Image 2_Unexpected estradiol decline during ovarian stimulation monitoring affects cumulative live birth.tiff by Haixiao Chen (12565087)

“…In both unmatched and matched cohorts, the CLBRs were significantly decreased (unmatched cohort: 66.3% versus 55%, P<0.001, adjusted OR 0.83, 95% CI: 0.76,0.91; matched cohort: 59% versus 55%, P = 0.003, adjusted OR 0.84, 95%CI: 0.75,0.94). …”

Image 8_Unexpected estradiol decline during ovarian stimulation monitoring affects cumulative live birth.tiff by Haixiao Chen (12565087)

“…In both unmatched and matched cohorts, the CLBRs were significantly decreased (unmatched cohort: 66.3% versus 55%, P<0.001, adjusted OR 0.83, 95% CI: 0.76,0.91; matched cohort: 59% versus 55%, P = 0.003, adjusted OR 0.84, 95%CI: 0.75,0.94). …”

Image 7_Unexpected estradiol decline during ovarian stimulation monitoring affects cumulative live birth.tiff by Haixiao Chen (12565087)

“…In both unmatched and matched cohorts, the CLBRs were significantly decreased (unmatched cohort: 66.3% versus 55%, P<0.001, adjusted OR 0.83, 95% CI: 0.76,0.91; matched cohort: 59% versus 55%, P = 0.003, adjusted OR 0.84, 95%CI: 0.75,0.94). …”

Image 10_Unexpected estradiol decline during ovarian stimulation monitoring affects cumulative live birth.tiff by Haixiao Chen (12565087)

“…In both unmatched and matched cohorts, the CLBRs were significantly decreased (unmatched cohort: 66.3% versus 55%, P<0.001, adjusted OR 0.83, 95% CI: 0.76,0.91; matched cohort: 59% versus 55%, P = 0.003, adjusted OR 0.84, 95%CI: 0.75,0.94). …”